Researchers find mechanism that fosters development of neuroendocrine prostate cancer, identify a dual-drug treatment that slowed tumor growth in lab tests A new study has uncovered promising ...

Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is ...

Many clinicians who treat men with prostate cancer may be unfamiliar with the term "treatment-emergent small-cell neuroendocrine prostate cancer" (t-SCNC). That's because it has been considered a rare ...

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory ...

Among men worldwide, prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. As the world's population ages, the number of prostate cancer patients is expected ...

It is not unusual for advanced prostate cancer to become resistant to treatment. Of these resistant cases, some progress to a specific form of the disease, which is particularly aggressive and deadly.

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer. McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI ...